(PDF) Five-Year Outcomes of Ranibizumab With Prompt or

Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema

American Journal of Ophthalmology - Netherlands

doi 10.1016/j.ajo.2015.12.025

Full Text

Abstract

Available in full text

Categories

Date

April 1, 2016

Authors

Susan B. Bressler

Adam R. Glassman

Talat Almukhtar

Neil M. Bressler

Frederick L. Ferris

Joseph M. Googe

Shailesh K. Gupta

Publisher

Elsevier BV

Related search

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Acta Ophthalmologica

English

Expanded 2-Year Follow-Up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

English

Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment

English

Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment: 5-Year Randomized Trial Results

English

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

English

Macular Laser Grid Alone Versus Combined With Intravitreal Triamcinolone Plus Bevacizumab for Diabetic Macular Edema

Journal of Pharmaceutical and Scientific Innovation

English

Green or Yellow Laser Treatment for Diabetic Macular Edema

English

Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema

JAMA Ophthalmology

English

Baseline Predictors for One-Year Visual Outcomes With Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration

English